ERBB2 and colorectal carcinoma: A study by Sirui Long et al. found that upregulation of certain HER2-related factors (e.g., ECM1) can activate the PI3K/Akt pathway, thereby conferring resistance to 5-FU in CRC cells (Long et al., 2022).